Your browser is no longer supported. Please, upgrade your browser.
Settings
MTNB Matinas BioPharma Holdings, Inc. daily Stock Chart
MTNB [NYSE]
Matinas BioPharma Holdings, Inc.
Index- P/E- EPS (ttm)-0.44 Insider Own13.30% Shs Outstand91.18M Perf Week-1.55%
Market Cap115.80M Forward P/E- EPS next Y-0.21 Insider Trans- Shs Float67.37M Perf Month-3.79%
Income-33.30M PEG- EPS next Q-0.05 Inst Own10.70% Short Float3.87% Perf Quarter-36.50%
Sales0.06M P/S1934.01 EPS this Y-17.20% Inst Trans- Short Ratio6.62 Perf Half Y-50.20%
Book/sh0.10 P/B12.70 EPS next Y27.60% ROA-218.70% Target Price7.67 Perf Year-22.09%
Cash/sh0.12 P/C10.25 EPS next 5Y- ROE-514.30% 52W Range1.01 - 3.99 Perf YTD-9.29%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-68.17% Beta-
Dividend %- Quick Ratio8.80 Sales past 5Y- Gross Margin- 52W Low25.74% ATR0.10
Employees10 Current Ratio8.80 Sales Q/Q- Oper. Margin- RSI (14)48.85 Volatility6.14% 7.71%
OptionableNo Debt/Eq0.01 EPS Q/Q-53.60% Profit Margin- Rel Volume0.32 Prev Close1.27
ShortableYes LT Debt/Eq0.01 EarningsAug 08 BMO Payout- Avg Volume394.37K Price1.27
Recom2.00 SMA20-1.85% SMA50-1.96% SMA200-42.32% Volume126,939 Change0.00%
Sep-19-17 09:20AM  Matinas BioPharma to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-12-17 07:30AM  Matinas BioPharma Retains JSB Partners to Pursue Strategic Options for MAT9001 GlobeNewswire
Aug-08-17 06:05AM  Matinas BioPharma Reports 2017 Second Quarter Financial Results and Reaffirms Clinical and Regulatory Strategy to Advance MAT2203 and MAT2501 GlobeNewswire +14.40%
05:50AM  Investor Network: Matinas BioPharma Holdings, Inc. to Host Earnings Call ACCESSWIRE
Aug-03-17 08:05AM  Matinas BioPharma to Present at the Canaccord Genuity 37th Annual Growth Conference GlobeNewswire +6.67%
Aug-01-17 08:30AM  Matinas BioPharma to Host Quarterly Update Conference Call GlobeNewswire
Jun-26-17 01:15PM  Here's Why Matinas BioPharma Holdings Inc. Is Losing Ground Today Motley Fool -27.80%
06:05AM  Matinas BioPharma Reports Topline Data from Phase 2 Clinical Study of Orally-Administered MAT2203 for the Treatment of Vulvovaginal Candidiasis GlobeNewswire
Jun-03-17 04:00PM  Matinas BioPharma Announces Interim Data from NIH-Conducted Phase 2a Clinical Study of Orally-Administered MAT2203 for the Treatment of Chronic Refractory Mucocutaneous Candidiasis GlobeNewswire
Jun-02-17 04:01PM  Matinas BioPharma Presents Positive Preclinical Efficacy Data of MAT2203 in Mouse Model of Cryptococcal Meningoencephalitis GlobeNewswire
Jun-01-17 07:05AM  Matinas BioPharma to Present at the 2017 Jefferies Global Healthcare Conference GlobeNewswire
May-30-17 08:05AM  Matinas BioPharma Announces Two Upcoming Data Presentations of Lead Product Candidate MAT2203 at The American Society for Microbiologys ASM Microbe 2017 Conference GlobeNewswire -11.33%
May-16-17 07:05AM  Matinas BioPharma Reports 2017 First Quarter Financial Results and Provides Corporate Update GlobeNewswire
Apr-24-17 07:00AM  Matinas BioPharma Presents Positive Preclinical Data of Orally Available DNA Vaccines at the 27th Annual European Congress of Clinical Microbiology and Infectious Diseases GlobeNewswire
Apr-18-17 07:01AM  Matinas BioPharma Appoints Dominick DiPaolo as Senior Vice President of Quality and Regulatory Compliance GlobeNewswire
Apr-11-17 08:30AM  MonoSol Rx Appoints James S. Scibetta to Board of Directors GlobeNewswire
Apr-03-17 07:36PM  Edited Transcript of MTNB earnings conference call or presentation 3-Apr-17 12:30pm GMT Thomson Reuters StreetEvents +5.42%
07:06AM  Matinas BioPharma Reports 2016 Financial Results and Provides Corporate Update GlobeNewswire
Mar-30-17 07:05AM  Matinas BioPharma Appoints Eric J. Ende, M.B.A, M.D. to its Board of Directors GlobeNewswire -7.09%
Mar-29-17 07:05AM  Matinas BioPharma to Host Fiscal Year 2016 Update Conference Call GlobeNewswire
Mar-28-17 07:35AM  Matinas BioPharma to Ring NYSE Closing Bell on March 29th, 2017 GlobeNewswire +15.69%
Mar-27-17 07:35AM  Matinas BioPharma Reports Positive Topline Data from Phase 1 Study of MAT2501 GlobeNewswire
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.